Rhythm touts Phase 3 win for rare obesity drug in people with brain damage
Rhythm Pharmaceuticals is looking to expand the potential market for its rare obesity treatment Imcivree beyond genetic disorders. The company said Monday the medicine reduced body weight in a late-stage trial of people with obesity ...
